ライフサイエンスコーパス: healthy donor

1 ds and to primary macrophages derived from a healthy donor.

2 progenitor cells (hCB-EPCs) from a separate, healthy donor.

3 nd established RA cohorts in comparison with healthy donors.

4 ases versus patients who received blood from healthy donors.

5 eutrophils were lower in APS and SLE than in healthy donors.

6 cell lines compared to primary B cells from healthy donors.

7 embled those for peripheral blood cells from healthy donors.

8 CTCL cell lines, but hardly in T cells from healthy donors.

9 subjects with prostate cancer compared with healthy donors.

10 with MM secreted higher amounts of IL-8 than healthy donors.

11 iversity and composition to resemble that of healthy donors.

12 s patients as compared to blood samples from healthy donors.

13 -Cas9 in induced pluripotent stem cells from healthy donors.

14 able or higher specificities than using Thai healthy donors.

15 ory Treg subsets was similar in patients and healthy donors.

16 mmune response against gB, gH, and gL within healthy donors.

17 ts whose tumors did not metastasize), and 37 healthy donors.

18 ssion profiling of 40 Treg cell subsets from healthy donors.

19 ver 5 time points and compared the values to healthy donors.

20 ity and sporulation were rescued by OME with healthy donors.

21 No cCAFs as defined were detected in healthy donors.

22 nally stable Tregs with yields comparable to healthy donors.

23 rotein expression profile similar to that of healthy donors.

24 ripotent stem cell (iPSC) lines derived from healthy donors.

25 ess higher levels of GzmB than do cells from healthy donors.

26 had resistance conferred to them by OME with healthy donors.

27 ukemia activity, from Ph(+) ALL patients and healthy donors.

28 d indistinctly with platelets from different healthy donors.

29 BL and LPL from patients in remission and/or healthy donors.

30 in quality and quantity between patients and healthy donors.

31 les collected from 42 trauma patients and 21 healthy donors.

32 file of primary lymphocytes from 5 different healthy donors.

33 an 25% cell death to normal lymphocytes from healthy donors.

34 sue samples from patients with psoriasis and healthy donors.

35 insulin, versus 20% and 37% respectively, in healthy donors.

36 ncarrier relatives from 40 families, and 200 healthy donors.

37 ification of physiological T cell targets in healthy donors.

38 ed bacterial burdens, compared with those of healthy donors.

39 on of IL-6 that, in contrast, is observed in healthy donors.

40 with patients with low serum AFP levels and healthy donors.

41 to the effects of type I IFN than cells from healthy donors.

42 ttern of HLA class I receptors compared with healthy donors.

43 with anti-viral T cells, and with those from healthy donors.

44 with total CMV-specific T-cell responses in healthy donors.

45 nsists of pooled immunoglobulin G (IgG) from healthy donors.

46 ence of such complexes in B-lymphocytes from healthy donors.

47 ), and NKp30 was induced to lower levels vs. healthy donors.

48 normal bone marrow CD34(+) progenitors from healthy donors.

49 s treated with the sera from PV patients and healthy donors.

50 mL of background level of detected CTCs from healthy donors.

51 es presented on MHC class II alleles from 17 healthy donors.

52 fractory multiple myeloma (MM) compared with healthy donors.

53 lood mononuclear cells from African American healthy donors.

54 -STAT5 (pSTAT5) flow cytometry compared with healthy donors.

55 ll as the adaptive immunity was evaluated in healthy donors.

56 tients without nosocomial pneumonia and with healthy donors.

57 lymphocytes specific to benzylpenicillin in healthy donors.

58 -stimulated human CD4+ T cells isolated from healthy donors.

59 with transfer of bone marrow (BM) cells from healthy donors.

60 and even memory CD4(+) T cell repertoire of healthy donors.

61 ndatory to ensure safe outcomes in otherwise healthy donors.

62 lpenicillin-specific CD4(+) T lymphocytes in healthy donors.

63 was little or no expression in synovium from healthy donors.

64 ar cells (PBMCs) were isolated from blood of healthy donors.

65 a tendency to overexpress CCR2 compared with healthy donors.

66 anisms in isolated human CD4(+) T cells from healthy donors.

67 tained at day 3 and compared with those from healthy donors.

68 nts with Myelodysplastic syndromes (MDS) and healthy donors.

69 and lower levels of AXL compared to DC from healthy donors.

70 kin samples from patients with psoriasis and healthy donors.

71 d cGVHD, compared with those who did not and healthy donors.

72 id arthritis and compared with synovium from healthy donors.

73 man peripheral blood monocytes isolated from healthy donors.

74 VHD compared with patients without cGVHD and healthy donors.

75 -FD and FD are present in the circulation of healthy donors.

76 performed on 29 patients with sepsis and 15 healthy donors.

77 ssions were analysed on human basophils from healthy donors.

78 2 polarization of CD8(+) T cells (TC2) from healthy donors.

79 t the ex vivo manufacture of multi-VSTs from healthy donors.

80 feration with CD40 stimulation compared with healthy donors.

81 ytes from 23 APS and 64 SLE patients, and 56 healthy donors.

82 a therapeutic preparation of pooled IgG from healthy donors.

83 rotein involved in iron acquisition, in four healthy donors.

84 significantly higher (P = 0.04) than that of healthy donors.

85 unoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P < 1.5 x 10(-5) for WM vs other c

86 ow) (9/41) B cells compared with age-matched healthy donors (1/33 and 2/33, respectively), which indi

87 ial pneumonia (16% [range: 6%-29%]) and with healthy donors (17% [range: 10%-29%]).

88 5 transcript signature that is distinct from healthy donors, 2) an IRF5-SLE risk haplotype defines th

89 ced cell death in Fas-sensitive T cells from healthy donors; (2) this inhibitory effect is also induc

90 pneumonia (4% [range: 2%-5%]) compared with healthy donors (20% [range: 15%-28%]).

91 eumonia (66% [range: 34%-69%]) compared with healthy donors (23% [range: 8%-61%]) and was not altered

92 patients who received fecal transplants from healthy donors (30.4%) and 5 of 25 controls (20.0%) achi

93 patients who received fecal transplants from healthy donors (41.2%) and 5 of 20 controls (25.0%) achi

94 of reduced expression of CD39 compared with healthy donors, a marker for the highly suppressive TREM

95 ized profiling of TCR beta repertoires in 39 healthy donors aged 6-90 y.

96 Importantly, not only were healthy donor allogeneic natural killer (NK) cells able

97 bility to control HCV infection, we analyzed healthy donor and HCV-infected donor NK-cell cytolytic a

98 of cytomegalovirus-specific CD8 T cells from healthy donor and patient after haploidentical stem cell

99 duced pluripotent stem cells (hiPSCs) from a healthy donor and patients with SVs.

100 fore and after DAA therapy, and also from 12 healthy donors and 12 individuals with HCV infection wit

101 Blood from 46 healthy donors and 120 patients with peanut allergy was

102 Semen samples were collected from 35 healthy donors and 35 infertile men at the Andrology lab

103 he sensor is demonstrated in cellular lines, healthy donors and a cancer patient.

104 mentary DNA into the IL2RG gene of HSCs from healthy donors and a subject with X-linked severe combin

105 s reside in bone marrow, hardly circulate in healthy donors and are absent in cord blood.

106 ade from the pooled plasma from thousands of healthy donors and are being tested in preclinical mouse

107 cells but is absent in resting T cells from healthy donors and B-cell lymphoma cells.

108 e central removal of autoreactive B cells in healthy donors and CVID patients.

109 esponse to all 7 PIV3-encoded antigens in 17 healthy donors and define a hierarchy of immunogenicity

110 al cells (ECs) from hiPS cells obtained from healthy donors and formed stable functional blood vessel

111 cultured human skin fibroblasts derived from healthy donors and from patients with progeria, a geneti

112 CSWB was evaluated in blood from healthy donors and from women with metastatic breast can

113 y and functional diversity of human Tregs in healthy donors and in patients after allogeneic hematopo

114 LPL were lower in patients with IBD than in healthy donors and in the healthy mucosa of patients wit

115 FLUX-naive HLA-B*57:01(+) and HLA-B*57:01(-) healthy donors and investigated the mechanism of T cell

116 ated peripheral blood mononuclear cells from healthy donors and observed that PA strains induce highe

117 within the viral-specific Th1 repertoire of healthy donors and patients with acute myeloid leukemia

118 Studies utilizing human plasma samples from healthy donors and patients with AML indicate that TTT-3

119 nhibited IL-17A secretion by Th17 cells from healthy donors and patients with ankylosing spondylitis

120 early- and late-stage pancreatic cancer from healthy donors and patients with benign pancreatic disea

121 f tendon-derived stromal cells isolated from healthy donors and patients with chronic tendinopathy.

122 Unlike control T cells, T4(+) T cells from healthy donors and patients with EOC were activated by a

123 Compared with healthy donors and patients with HCV infection without C

124 ts at all stages of Lyme disease, as well as healthy donors and patients with look-alike diseases.

125 d by bronchoscopy from bronchial biopsies of healthy donors and patients with mild and severe asthma.

126 Blood obtained from healthy donors and patients with PDAC was therefore subj

127 Compared with healthy donors and patients with reactive monocytosis or

128 likely to produce IL-10 than were Bregs from healthy donors and patients without cGVHD.

129 Atorvastatin administration in healthy donors and recipients was not associated with an

130 ecules, NKG2A, CD8, and CD57, on NK cells in healthy donors and seven patients with deficient HLA cla

131 Blood from healthy donors and SLE patients have similar circulating

132 anscript variants from purified monocytes of healthy donors and SLE patients to generate an IRF5 vari

133 te-derived macrophages (HMDMs) obtained from healthy donors and SLE patients.

134 with UC who received fecal transplants from healthy donors and those who received their own fecal mi

135 lear cells (PBMCs) obtained from HLA-A*02(+) healthy donors and/or HLA-A*02(+) cancer patients.

136 effective against the fungus than those from healthy donors, and broader heterogeneity exists between

137 s, co-localizes with antigen on B cells from healthy donors, and is present on antigen-positive B cel

138 d serum samples of xenotransplanted mice, of healthy donors, and of patients with uveal melanoma duri

139 et cells was greater than that of cells from healthy donors, and this localized to the African Americ

140 pheral blood lymphocytes (PBLs) derived from healthy donors as well as chronically infected HCV patie

141 sequencing data using blood-derived DNA from healthy donors as well as DNA from tumor samples, we pre

142 We collected plasma from healthy donors as well as from subjects with respiratory

143 l subsets isolated ex vivo from the blood of healthy donors, as well as in vitro-polarized T-cell sub

144 Bacterial stimulation of Tip-DC from healthy donors, atopic dermatitis, or psoriasis patients

145 Stimulation of healthy donor B cells with CD40L, anti-IgM, IL-21, CpG,

146 g in 57 WM patients and compared findings to healthy donor B cells.

147 Monocytes purified from healthy donor blood samples were cultured for 4 to 96 ho

148 ected a baseline of 2-5 CD138(+) cells/mL in healthy donor blood, with significantly higher numbers i

149 ivated memory Tregs sorted from the blood of healthy donors, but it does not affect their proliferati

150 lus proteins Crf1 and catalase 1 in 18 of 24 healthy donors by intracellular staining for interferon

151 D8(+) T cells, so-called Tc2 cells, which in healthy donors can only be detected at very low levels,

152 nanomolar levels of spermine in human urine (healthy donors, cancer patients) is reported.

153 Transfer of these TCRs to healthy donor CD4+ T cells conferred high antigen sensit

154 w diminished levels of miR-29b compared with healthy donor cells.

155 Among healthy donors, circulating TCR sequence diversity remai

156 LAMF7-CAR T cells prepared from patients and healthy donors confer potent antimyeloma reactivity.

157 collected samples of ILD tissue (n = 45) and healthy donor control samples (n = 10), as well as fibro

158 cells of RRMS patients at levels similar to healthy donor controls.

159 65) following CD40 stimulation compared with healthy donor controls.

160 still recognize I/i antigens, whereas their healthy donor counterparts harbored FWR1 mutations aboli

161 +)CD4(+) cells (R = 0.80) and monocytes from healthy donors cultured with IL-4 differentiated into fi

162 sis resist suppression by patient-derived or healthy donor-derived ex vivo Tregs.

163 roke patients inhibited the proliferation of healthy donor-derived lymphocytes, an effect which was a

164 mulated ADAM17-dependant CD163 shedding from healthy donor-derived monocytes.

165 ded Vgamma9Vdelta2 T cells from patients and healthy donors displayed similar phenotype and destroyed

166 Replacement of the diseased cells with a healthy donor endothelium is the only currently availabl

167 IFN-gamma secretion assay from HLA-unmatched healthy donors exhibited a high level of anti-CMV potenc

168 Transplantation of healthy donor fecal material in patients with CDI may re

169 idosis patients from Thailand along with 188 healthy donors from Thailand and 90 healthy donors from

170 with 188 healthy donors from Thailand and 90 healthy donors from the United States as controls.

171 identified by comparing cancer patients' and healthy donors' global peptide profiles of antibody spec

172 mal localization clearly discriminated among healthy donors (>75%), A-T heterozygotes (40%-56%), and

173 light chain (NFL), were elevated compared to healthy donor (HD) controls.

174 xicity in PBMC from CLL patients compared to healthy donors (HD).

175 n CD4 T cells from SS patients compared with healthy donors (HD).

176 is of myoglobin (Mb) in 10 plasma samples of healthy donors (HDs) and 14 plasma samples of patients w

177 their potential as immunological markers in healthy donors (HDs) and patients with rheumatoid arthri

178 levels of SLPI and IFN-gamma were studied in healthy donors (HDs) and TB patients.

179 Samples from 14 healthy donors (HDs), 40 PHI patients, 17 Chronics, and

180 y normal WPBs compared with control BOECs of healthy donors; however, EIEE4 BOECs displayed significa

181 her the IRF5 transcript profile expressed in healthy donor immune cells is different from that expres

182 ree IGHV4-34*01 IgG antibodies isolated from healthy donors immunized against foreign rhesus D alloan

183 stromal cells (MSCs) to these patients from healthy donors in a double-blind, placebo-controlled stu

184 al infarction (AMI) and in control plasma of healthy donors in order to demonstrate the potential med

185 but were as effective as cells obtained from healthy donors in reducing inflammation and remodeling,

186 activation of primary KIR2DL3+ NK cells from healthy donors in response to HLA-C*03:04+ target cells

187 upplemented with concentrated platelets from healthy donors in vitro, raising platelet counts by 0% (

188 ulosis produce less IFN-gamma, compared with healthy donors, in response to mycobacterial antigens, a

189 ncing in macrophages and CD4(+) T cells from healthy donors increases HIV-1 RNA stability, rendering

190 cific CD4(+) T lymphocytes in 9 of 10 tested healthy donors irrespective of their HLA typing, with a

191 cal microbiota transplantation, stool from a healthy donor is transplanted to treat a variety of dysb

192 n addition, the use of a pool of faeces from healthy donors is strongly recommended to improve repeat

193 ody-predicted structural models across three healthy donors led to a number of key findings: (i) VH a

194 cleavage and TLR4 signaling intermediates in healthy donor leukocytes and either a TLR4 inhibitor or

195 and inhibitory receptor repertoire to normal healthy donor levels.

196 positive versus HCV-negative HCC patients or healthy donor livers.

197 th recombinant CCNB1 of T cells collected in healthy donors (long-term T cell assays).

198 MCs were obtained from IPF lung explants and healthy donor lungs that were not used for transplantati

199 s lymphocytes compared to those grafted with healthy donors lymphocytes.

200 ng/mL [range, 201-469 ng/mL]) (P < .001) and healthy donors (median level, 285 ng/mL [range, 65-463 n

201 s-mediated apoptosis could be transferred to healthy donor memory B-cells by co-culturing these cells

202 s showed similar (MS patients) or increased (healthy donors) MHC-II expression as class-switched memo

203 n human lung tissue from patients with COPD, healthy donors, mice, and guinea pigs.

204 CLL cells induced IDO(hi) MDSCs from healthy donor monocytes suggesting bidirectional crossta

205 itis C virus-infected patients (n = 17), and healthy donors (n = 173).

206 rotocol validation was assessed in saliva of healthy donors (n = 21) by enzyme-linked immunosorbent a

207 ared them with patients with KS (n = 24) and healthy donors (n = 29).

208 liferation of CD4(+) and CD8(+) T cells from healthy donors (n = 30) and treated HIV(+) donors (n = 2

209 ted by other flaviviruses, other viruses, or healthy donors (n = 540), the specificity was 95.9%.

210 linical atherosclerosis patients (n = 8) and healthy donors (n = 8) in the LVAD study (NCT02174133, N

211 we found that ILT4 up-regulation induced on healthy donor neutrophils following stimulation was impa

212 e cells (CD4(+) T cells) to HCMV proteins in healthy donors of all ages, and we demonstrate that the

213 les from healthy newborns, and 240 DBSs from healthy donors of different age ranges were examined.

214 ylated STAT5 were increased by IFN-alpha8 in healthy donors only.

215 ore, we developed a new paradigm by grafting healthy donor or multiple sclerosis patient lymphocytes

216 neering of peripheral blood lymphocytes from healthy donors or chronically infected HCV patients resu

217 henotype inexperienced cells, as compared to healthy donors or cured HCV patients.

218 numbers than seen in the peripheral blood of healthy donors or in patients before transplant.

219 re obtained from bronchoalveolar lavage from healthy donors or patients with COPD and challenged with

220 to groups that underwent FMT with feces from healthy donors or were given autologous fecal microbiota

221 en after a damaged kidney is replaced with a healthy donor organ.

222 inhibitory effect was observed in PBMCs from healthy donors over a range of concentrations of sorafen

223 1-mutation carriers compared with cells from healthy donors (p = 0.0014).

224 Our results indicated that in healthy-donor PBMCs, mature-activated T cells were more

225 cells induced the development of MDSCs from healthy donor peripheral blood mononuclear cells, confir

226 in vitro, healthy donor peripheral blood mononuclear cells, purifi

227 PMPs were cocultured with healthy donor peripheral blood-derived Tregs that were s

228 In healthy donors, PF4/heparin complexes bind preferentiall

229 l IgG formulation prepared from thousands of healthy donors' plasma, is extensively used for the immu

230 and dendritic cells from peripheral blood of healthy donors produce IL-12 and other proinflammatory c

231 responded by interferon-gamma, whereas most healthy donors produced interleukin-10 only.

232 PAS of 10 healthy donors provided [Ca(t)]i data for training 10 ne

233 Our results provide an initial assessment of healthy donor reference values for induced cytokines and

234 n the FMT group was similar to that of their healthy donors; remission was associated with proportion

235 Studies using PBMCs from healthy donors revealed that downregulation of CD32B on

236 Exosomes derived from GIST patients but not healthy donors show enhanced MMP1 secretion by smooth mu

237 -treated peripheral blood lymphocytes from a healthy donor showed that Tat significantly activates ex

238 iller cells from KIR3DS1(+)/HLA-Bw4-80Ile(+) healthy donors showed a 2-fold increased capacity to inh

239 T cell responses from healthy donors showed a high degree of cross-reactivity

240 artment displayed CD33 at higher levels than healthy donor stem cells (P = .047).

241 Fecal microbiota transplantation, where healthy donor stool is transplanted into a patient, is a

242 om patients with T1D but scantly detected in healthy donor subjects.

243 pattern of responses was obtained among the healthy donors, suggesting rather a competition than a s

244 estricted by the lack of biliary tissue from healthy donors suitable for surgical reconstruction.

245 Compared with healthy donors, T-cell expanded in peripheral repertoire

246 CD4(+) and/or CD8(+) T cells from 75% of the healthy donors tested.

247 ool of serum sCD27 is shown to be greater in healthy donors than in cancer patients.

248 ells isolated from human PBMCs obtained from healthy donors that had been stimulated by their respect

249 bsets from patients with type 1 diabetes and healthy donors, that patients have shorter TCRB compleme

250 , primary samples, and CD341 stem cells from healthy donors, the authors support the notion that aspa

251 used retrospective serial blood samples from healthy donors to investigate this topic.

252 The ability of human gammadelta T cells from healthy donors to kill pancreatic ductal adenocarcinoma

253 xposed purified NK cells and full PBMCs from healthy donors to PLT-Ecto.

254 We validated this strategy using cells from healthy donors to retrieve human antibodies against teta

255 switch the phenotype of blood NK cells from healthy donors to the phenotype associated with TILN.

256 X-reacting T cells from 10 HLA-B( *)57:01(+) healthy donors toward autologous target cells and HLA-B(

257 ART1-specific CD8 T cells were expanded from healthy donors using artificial APCs.

258 have shown that the reactivity of sera from healthy donors varies according to assay type and indica

259 rded attomolar concentrations of IFNalpha in healthy donors, viral infection, and complex and monogen

260 ith dementia versus recipients of blood from healthy donors was 1.04 (95% CI, 0.99 to 1.09).

261 tal Th cells or different Th cell subsets of healthy donors was analyzed in vitro.

262 rity-matched intensive care patients, and 67 healthy donors was prospectively enrolled for flow cytom

263 icipants 14 to 21 days after AMI and BM from healthy donors was used as a reference.

264 ved macrophages (MDMs), and neutrophils from healthy donors, we assessed phagocytosis and killing of

265 Using primary human blood monocytes from healthy donors, we identified ANXA1 as a potent CD14(+)C

266 e acute response to influenza vaccination in healthy donors, we identify the presence of phenotypic C

267 rticle-depleted plasma samples from the same healthy donors were analyzed in parallel.

268 In total, 320 CLL patients and 449 healthy donors were analyzed.

269 on in vitro, peripheral blood monocytes from healthy donors were cultured in the presence of cord blo

270 Peripheral blood mononuclear cells from healthy donors were cultured with Mycobacterium tubercul

271 Monocytes from healthy donors were differentiated toward M1-like or M2-

272 Fifty-seven patients and 20 healthy donors were enrolled.

273 Activated human CD4+ T cells from healthy donors were exposed to 1 muM methylprednisolone

274 murine splenocytes and from blood samples of healthy donors were incubated for 8 days under Th2-like

275 eral blood mononuclear cells (PBMCs) from 20 healthy donors were infected in vitro with HIV-1BaL in t

276 Primary macrophages from healthy donors were infected with L. panamensis strains

277 ed DC obtained from 18 HNSCC patients and 12 healthy donors were matured using IRX-2 or a mix of TNF-

278 Cell samples from healthy donors were obtained from HemaCare (Van Nuys, Ca

279 Sera from 29 breast cancer patients and 28 healthy donors were screened in sandwich immunoassays on

280 xisting human CD4(+) and CD8(+) T cells from healthy donors were shown to recognize and respond to th

281 DCs of patients with XLA and healthy donors were stimulated via TLR4/9 and evaluated

282 Stool specimens from healthy donors were treated with ethanol to eliminate pa

283 Twelve normal corneal buttons from healthy donors were used as controls.

284 es from 68 individuals (58 PDAC patients, 10 healthy donors) were analyzed; CTCs were present in pati

285 higher prothrombin and factor X levels than healthy donors, whereas levels were unchanged in primary

286 predominantly derived from megakaryocytes in healthy donors, whereas microparticles derived from acti

287 of patients with CVID compared with those of healthy donors, whereas the pERK increment induced by BC

288 min induced NETs release by neutrophils from healthy donors which was not suppressed by inhibitors of

289 work, we found that semen exosomes (SE) from healthy donors who do not use illicit drugs potently inh

290 An AUC of 0.73 was obtained when comparing healthy donors with biopsy-positive patients.

291 y, treatment of CD4(+) T cells isolated from healthy donors with both HIV-1 virions and cocaine signi

292 e studied NET production in neutrophils from healthy donors with inhibitors of molecules crucial to P

293 n-10-producing dendritic cells obtained from healthy donors with peripheral blood mononuclear cells (

294 activation-induced FOXP3 in Tconv cells from healthy donors with small interfering RNAagainst FOXP3.

295 Stimulation of CD4+ T cells isolated from healthy donors with synthetic and endogenous LXR agonist

296 assays were higher background reactivity in healthy donors with the polyclonal assay and an increase

297 ecal bacterial diversity, similar to that in healthy donors, with an increase in Bacteroidetes specie

298 tokine patterns were shared among a group of healthy donors, with minimal intraindividual and interin

299 enhances the manufacture of multi-VSTs from healthy donors without altering their phenotype or funct

300 Compared with healthy donors, WM patient samples showed greatly enhanc